Dyax Receives FDA Approval to Expand Use of KALBITOR® (ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema to Patients 12 Years of Age and Older
April 03, 2014 at 16:12 PM EDT
Dyax Corp. (NASDAQ: DYAX) today announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication ...
